Philip Breitfeld

Philip P. Breitfeld, MD, serves as the Chief Medical Officer at Radiomer Therapeutics and Allterum Therapeutics, in addition to holding a position on the Scientific Advisory Board of MMS. As a longstanding member of the Board of Directors for Champions Oncology, Philip has contributed to developing advanced solutions for oncology drug utilization. Philip's prior leadership roles include Managing Director of The Breitfeld Group, LLC, and Vice President positions at IQVIA, where responsibilities encompassed global therapeutic excellence and oncology strategy. Past experience also includes significant roles in oncology development at EMD Serono and BioCryst Pharmaceuticals, along with tenure as an Associate Professor at Duke University Medical Center. Philip's educational background encompasses degrees in Chemistry from Princeton University and Medicine from the University of Rochester, supplemented by advanced studies at Harvard Medical School and Indiana University School of Medicine.